1. Home
  2. HPQ vs BIIB Comparison

HPQ vs BIIB Comparison

Compare HPQ & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HP Inc.

HPQ

HP Inc.

HOLD

Current Price

$24.37

Market Cap

22.9B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$181.70

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HPQ
BIIB
Founded
1939
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.9B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
HPQ
BIIB
Price
$24.37
$181.70
Analyst Decision
Hold
Buy
Analyst Count
13
23
Target Price
$25.85
$176.48
AVG Volume (30 Days)
13.6M
2.0M
Earning Date
11-25-2025
10-30-2025
Dividend Yield
4.91%
N/A
EPS Growth
N/A
N/A
EPS
2.65
10.97
Revenue
$55,295,000,000.00
$10,065,900,000.00
Revenue This Year
$2.37
$2.97
Revenue Next Year
$1.71
N/A
P/E Ratio
$9.22
$16.59
Revenue Growth
3.24
4.77
52 Week Low
$21.21
$110.04
52 Week High
$36.93
$185.17

Technical Indicators

Market Signals
Indicator
HPQ
BIIB
Relative Strength Index (RSI) 43.89 80.16
Support Level $23.50 $165.75
Resistance Level $25.05 $183.93
Average True Range (ATR) 0.77 5.46
MACD 0.07 1.68
Stochastic Oscillator 48.32 89.52

Price Performance

Historical Comparison
HPQ
BIIB

About HPQ HP Inc.

HP (formerly Hewlett-Packard) is a behemoth in the PC and printing markets. It has focused on these markets since it exited IT infrastructure in 2015 with the split from Hewlett Packard Enterprise. HP focuses on the commercial market, but maintains sales of consumer devices and printers. The firm has a broad and global customer base, with only one third of sales coming from the US. HP completely outsources manufacturing and relies heavily on channel partners for its sales and marketing.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: